Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
Authors
Keywords
-
Journal
Frontiers in Cell and Developmental Biology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-06-17
DOI
10.3389/fcell.2020.00486
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib
- (2020) P.A. Ascierto et al. ANNALS OF ONCOLOGY
- Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma
- (2020) S. Ugurel et al. ANNALS OF ONCOLOGY
- T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells
- (2020) Karol Granados et al. BRITISH JOURNAL OF CANCER
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
- (2020) Paolo A. Ascierto et al. EUROPEAN JOURNAL OF CANCER
- H3K27me3-mediated PGC1α gene silencing promotes melanoma invasion through WNT5A and YAP
- (2020) Chi Luo et al. JOURNAL OF CLINICAL INVESTIGATION
- HDAC3 functions as a positive regulator in Notch signal transduction
- (2020) Francesca Ferrante et al. NUCLEIC ACIDS RESEARCH
- Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study
- (2020) Laura Ridolfi et al. Journal of Geriatric Oncology
- Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
- (2020) Xu-Wen Guan et al. Cell Death & Disease
- BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages
- (2020) Xi Li et al. Frontiers in Immunology
- Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma
- (2020) Mohamad Krayem et al. Cancers
- Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
- (2020) Mariusz L. Hartman et al. Cells
- Silencing of STAT3 via Peptidomimetic LNP-Mediated Systemic Delivery of RNAi Downregulates PD-L1 and Inhibits Melanoma Growth
- (2020) Ehexige Ehexige et al. Biomolecules
- Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma
- (2020) Yu Hei et al. International Journal of Nanomedicine
- TRAF6 Activates Fibroblasts to Cancer-Associated Fibroblasts through FGF19 in Tumor Microenvironment to Benefit the Malignant Phenotype of Melanoma Cells
- (2020) Yeye Guo et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Acetylation of CCAR2 establishes a BET/BRD9 acetyl switch in response to combined deacetylase and bromodomain inhibition
- (2019) Praveen Rajendran et al. CANCER RESEARCH
- Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
- (2019) Jonathan L. Kaufman et al. Blood Cancer Journal
- Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
- (2019) Ulrich Keilholz et al. Journal for ImmunoTherapy of Cancer
- HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics
- (2019) Andressa S. Laino et al. Journal for ImmunoTherapy of Cancer
- MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas
- (2019) Ophélia Maertens et al. Cancer Discovery
- HDAC3 inhibition up-regulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy
- (2019) Siyu Deng et al. MOLECULAR CANCER THERAPEUTICS
- Negative Regulatory Loop between Microphthalmia-Associated Transcription Factor (MITF) and Notch Signaling
- (2019) Tamar Golan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cancer‐associated fibroblasts promote PD‐L1 expression in mice cancer cells via secreting CXCL5
- (2019) Ziqian Li et al. INTERNATIONAL JOURNAL OF CANCER
- HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy
- (2019) Michael F. Emmons et al. CANCER RESEARCH
- Regulation of OCT2 transcriptional repression by histone acetylation in renal cell carcinoma
- (2019) Qianying Zhu et al. Epigenetics
- Joint action of miR‐126 and MAPK / PI 3K inhibitors against metastatic melanoma
- (2019) Francesca Pedini et al. Molecular Oncology
- The next‐generation BET inhibitor, PLX51107, delays melanoma growth in a CD8‐mediated manner
- (2019) Dan A. Erkes et al. Pigment Cell & Melanoma Research
- Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer
- (2019) Abdullah Al Emran et al. Epigenomics
- H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy
- (2019) Marta Hałasa et al. Cells
- Melanoma extracellular vesicles generate immunosuppressive myeloid cells by PD-L1 upregulation via TLR4 signaling
- (2019) Viktor Fleming et al. CANCER RESEARCH
- HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma
- (2019) Fernanda Faião-Flores et al. CLINICAL CANCER RESEARCH
- Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab
- (2019) Omid Hamid et al. CLINICAL CANCER RESEARCH
- Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells
- (2019) Shotaro Eto et al. PLoS One
- Regression of BRAF V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases
- (2019) Peter Y.M. Woo et al. Oncotarget
- Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
- (2019) Tessa Knox et al. Scientific Reports
- Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance
- (2019) Yapeng Su et al. PLoS Computational Biology
- ORAL 5-AZACYTIDINE AND ROMIDEPSIN EXHIBIT MARKED ACTIVITY IN PATIENTS WITH PTCL: A MULTICENTER PHASE I STUDY
- (2019) Owen A O'Connor et al. BLOOD
- Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer
- (2019) Kai Xiong et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell–mediated tumor regression
- (2019) Anders Etzerodt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Distinct transcriptional programming drive response to MAPK inhibition in BRAFV600 mutant melanoma patient derived xenografts
- (2019) Tianshu Feng et al. MOLECULAR CANCER THERAPEUTICS
- BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts
- (2019) Daofu Feng et al. ONCOGENE
- HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells
- (2019) Corrado Caslini et al. ONCOGENE
- Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation
- (2019) Zhexi Chi et al. PHARMACOLOGICAL RESEARCH
- Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion
- (2019) Andrew J. Freeman et al. Cell Reports
- Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
- (2019) Baptiste Louveau et al. Cancers
- Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy
- (2019) Adeleye O. Adeshakin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer
- (2019) Yue Xue et al. BRITISH JOURNAL OF CANCER
- Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
- (2019) Alessandro Rossi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
- (2019) Maria Grazia Atzori et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Prevalence of NRAS Mutation, PD‐L1 Expression and Amplification, and Overall Survival Analysis in 36 Primary Vaginal Melanomas
- (2019) Hai‐Yun Wang et al. ONCOLOGIST
- MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity
- (2019) Mark Yarchoan et al. PLoS One
- MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-γ-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells
- (2019) Chen et al. Cancers
- Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
- (2019) Ewelina Dratkiewicz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
- (2019) S. Napolitano et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Actinomycin D and Telmisartan Combination Targets Lung Cancer Stem Cells Through the Wnt/Beta Catenin Pathway
- (2019) Ryan Green et al. Scientific Reports
- Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung
- (2018) Sanjeeve Balasubramaniam et al. ANTI-CANCER DRUGS
- HDAC6 interacts with PTPN1 to enhance melanoma cells progression
- (2018) Jiaqi Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines
- (2018) Jingjing Xiao et al. BMC CANCER
- An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
- (2018) Liqin Wang et al. CELL
- Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1
- (2018) Zike Yang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
- (2018) Jooeun Bae et al. LEUKEMIA
- Identification of an HLA-A2-restricted CD147 epitope that can induce specific CTL cytotoxicity against drug resistant MCF-7/Adr cells
- (2018) Chuang Qu et al. Oncology Letters
- HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants
- (2018) Andrew Nguyen et al. Cell Reports
- YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
- (2018) Min Hwan Kim et al. Cancer Immunology Research
- Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
- (2018) Viktor Fleming et al. Frontiers in Immunology
- Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance
- (2018) Farzana Ahmed et al. Frontiers in Oncology
- Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy
- (2018) Alexander Badamchi-Zadeh et al. JOURNAL OF IMMUNOLOGY
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Class I and II Histone Deacetylase Inhibitors Differentially Regulate Thermogenic Gene Expression in Brown Adipocytes
- (2018) Anubama Rajan et al. Scientific Reports
- HDAC4 degradation by combined TRAIL and valproic acid treatment induces apoptotic cell death of TRAIL-resistant head and neck cancer cells
- (2018) Bok-Soon Lee et al. Scientific Reports
- Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A
- (2018) ELIZABETH A. MAZZIO et al. Cancer Genomics & Proteomics
- Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
- (2018) Seong-Ho Kang et al. OncoImmunology
- miR-146a Controls Immune Response in the Melanoma Microenvironment
- (2018) Justin Mastroianni et al. CANCER RESEARCH
- Potent anti‐proliferative effect of fatty‐acid derivative AIC ‐47 on leukemic mice harboring BCR ‐ ABL mutation
- (2018) Haruka Shinohara et al. CANCER SCIENCE
- BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials
- (2018) Taku Fujimura et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma
- (2018) Michael P. Smith et al. Pigment Cell & Melanoma Research
- Suppression of miR-22, a tumor suppressor in cervical cancer, by human papillomavirus 16 E6 via a p53/miR-22/HDAC6 pathway
- (2018) Weerayut Wongjampa et al. PLoS One
- HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
- (2017) Stuart J. Gallagher et al. INTERNATIONAL JOURNAL OF CANCER
- Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer
- (2017) Changhong Liu et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity
- (2017) Jheng-Yu Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma
- (2017) Antonio Ahn et al. MOLECULAR CANCER THERAPEUTICS
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
- (2017) Meredith L. Stone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Histone deacetylase 5 promotes the migration and invasion of hepatocellular carcinoma via increasing the transcription of hypoxia-inducible factor-1α under hypoxia condition
- (2017) Ming Ye et al. TUMOR BIOLOGY
- Distinct histone modifications denote early stress-induced drug tolerance in cancer
- (2017) Abdullah Al Emran et al. Oncotarget
- HDAC10 promotes angiogenesis in endothelial cells through the PTPN22/ERK axis
- (2017) Baoyu Duan et al. Oncotarget
- The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3β and decreasing the expression of cyclinD1
- (2017) Youngmi Kim et al. Oncotarget
- The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
- (2017) Laurence Booth et al. Oncotarget
- Blockade of the LRP16-PKR-NF-κB signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy
- (2017) Xiaolei Li et al. eLife
- Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors
- (2017) Sheila López-Cobo et al. OncoImmunology
- Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK
- (2017) Luca Hegedüs et al. Frontiers in Oncology
- Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
- (2017) Vikas Dembla et al. Scientific Reports
- Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy
- (2016) Michael P. Smith et al. CANCER CELL
- Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance
- (2016) A. Krumm et al. CANCER RESEARCH
- ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
- (2016) Geoffrey Richard et al. EMBO Molecular Medicine
- Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
- (2016) Sarah J. Welsh et al. EUROPEAN JOURNAL OF CANCER
- Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells
- (2016) Jiaqi Liu et al. Journal of Translational Medicine
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Essential role of HDAC6 in the regulation of PD-L1 in melanoma
- (2016) M. Lienlaf et al. Molecular Oncology
- Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma
- (2016) Bang-Ping Jiang et al. Small
- miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2
- (2016) Youngmi Kim et al. Oncotarget
- MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma
- (2016) Johannes Fabian et al. Oncotarget
- Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
- (2016) Kotryna Seip et al. Oncotarget
- Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells
- (2016) Sofia R. Gameiro et al. Oncotarget
- A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
- (2016) Nageatte Ibrahim et al. Cancer Medicine
- Microphthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation
- (2015) Jiri Vachtenheim et al. EXPERIMENTAL DERMATOLOGY
- Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function
- (2015) Eva Sahakian et al. MOLECULAR IMMUNOLOGY
- Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
- (2015) K.V. Woan et al. Molecular Oncology
- Tubulin Beta3 Serves as a Target of HDAC3 and Mediates Resistance to Microtubule-Targeting Drugs
- (2015) Youngmi Kim et al. MOLECULES AND CELLS
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- HDAC3 acts as a negative regulator of angiogenesis
- (2014) Deokbum Park et al. BMB Reports
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- (2014) H. Rizos et al. CLINICAL CANCER RESEARCH
- Phase II trial of vorinostat in advanced melanoma
- (2014) N. B. Haas et al. INVESTIGATIONAL NEW DRUGS
- miR-326-Histone Deacetylase-3 Feedback Loop Regulates the Invasion and Tumorigenic and Angiogenic Response to Anti-cancer Drugs
- (2014) Youngmi Kim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
- (2013) Alexander Roesch et al. CANCER CELL
- A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
- (2013) B. Venugopal et al. CLINICAL CANCER RESEARCH
- A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
- (2013) H. Shi et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Role of Histone Acetylation in the Stimulatory Effect of Valproic Acid on Vascular Endothelial Tissue-Type Plasminogen Activator Expression
- (2012) Pia Larsson et al. PLoS One
- Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy
- (2011) M Gupta et al. LEUKEMIA
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Cancer/Testis Antigen CAGE Exerts Negative Regulation on p53 Expression through HDAC2 and Confers Resistance to Anti-cancer Drugs
- (2010) Youngmi Kim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started